Concepedia

Ming Poi

MP

Statistics

Publications

40

Citations

1.3K

H-Index

22

Active since

1999

Affiliations

The Ohio State University(Current)

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

The Ohio State University Wexner Medical Center

Emory University

American Association of Colleges of Pharmacy

Ming Poi is an author at The Ohio State University specializing in medicine, oncology, and molecular oncology.

Publications per year

1999–2023

40

Publications

40

Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity

Ming Poi, Xiaochun Sun, Andrea Gaedigk et al. · Human Molecular Genetics · 2013 · 123 citations · Full text

Medicine, Genetics, Pharmacology +15

Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i> -Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial

Naifa L. Busaidy, Bhavana Konda, Lai Wei et al. · Thyroid · 2022 · 106 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury

Yuntao Bai, Laura A. Jayne, Ralph D. Hector et al. · Nature Communications · 2020 · 63 citations · Full text

Medicine, Cell Biology, Nephrology +17

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Douglas W. Sborov, Alessandro Canella, Erinn M. Hade et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2017 · 56 citations

Medicine, Hematology, Pharmacology +16

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK

Long‐Sheng Chang, Janet L. Oblinger, Abbi E. Smith et al. · PLoS ONE · 2021 · 54 citations · Full text

Medicine, Oncology, Pharmacology +15

1–5 of 40